This information sheet does not need to be faxed or submitted with the Prior Authorization Request (PAR) form as it is intended to provide information only. Refer to the Synagis® 2022-2023 Provider Bulletin for more information.

The 2022-2023 Synagis® (palivizumab) season will begin October 4, 2022 and end April 28, 2023. Health First Colorado will approve requests for a maximum of five (5) doses, at a dosing interval of no fewer than 26 days between injections. Requests for doses exceeding the five (5) dose maximum or beyond the season end date will be DENIED. Providers should be aware that the Colorado Respiratory Syncytial Virus (RSV) season typically has a later onset (i.e., starts closer to the end of December) and should schedule their Synagis® doses accordingly. Area virology trend reporting is available on the Centers for Disease Control and Prevention (CDC) website.

Effective October 4th, 2022, Health First Colorado will begin accepting PARs for Synagis®. All requests for Synagis® (Palivizumab) require prior authorization. All requests for administration in the home should be submitted for payment through the pharmacy benefit, which must be submitted on the Health First Colorado Synagis® Pharmacy Benefit PAR form. The form can be found in the Provider Services Forms section of the Department’s website. No other forms will be accepted. The form can be faxed to 1-800-424-5881. All Synagis® Pharmacy benefit PARs must be signed by the prescribing physician, even if submitted by an agent of the prescriber. In the event that the prescriber can attest to a documented home health service access issue for the member, pharmacy benefit PARs for office administration will be considered. All other requests for administration in the provider’s office or facility should be submitted through the Colorado PAR Program. Please visit https://hcpf.colorado.gov/par for information on how to submit a medical PAR for Synagis®.

The Department is continuing use of coverage criteria based on the recommendations of the American Academy of Pediatrics (AAP) 2014 for Respiratory Syncytial Virus (RSV) prophylactic therapy. These recommendations have been updated since the 2009 AAP guidelines. Per the AAP “Evidence of these falling rates of RSV hospitalizations, along with new data about which children are at highest risk of RSV hospitalization, guided the AAP recommendation that palivizumab prophylaxis be limited to infants born before 29 weeks gestation, and to infants with certain chronic illnesses like congenital heart disease or chronic lung disease.” The Department has reviewed the guidelines and evidence and agrees with the AAP statement. Synagis® is used to prevent serious lower respiratory tract disease caused by RSV in pediatric members at high risk for RSV disease. Synagis® is administered by intramuscular injections, at 15 mg per kg of body weight, once a month during expected periods of RSV frequency in the community. Requests for Synagis® that do not meet the AAP indications listed on the Health First Colorado Synagis® Pharmacy Benefit PAR Form online will be DENIED. To request additional clinical consideration after a pharmacy benefit denial, first contact Magellan Rx Management Pharmacy Call Center (1-800-434-5725) to request an expanded (pharmacist) review. Members or providers may appeal Synagis® prior authorization denials through the normal appeals process.

**Dispensing and Prior Authorization of Synagis® Immune Globulin**

- Please note that no more than one (1) 50mg vial will be allowed per month through the pharmacy benefit. As an example, if 100mg is needed use a 100mg vial and not two (2) 50mg vials. The chart below provides details regarding the pharmacy coverage guidelines.

**Dispensing Guide (for Pharmacy Administration Only)**

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dosage</th>
<th>Dispense Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 3.3 kg</td>
<td>Up to 49.5 mg</td>
<td>1 x 50 mg vial</td>
</tr>
<tr>
<td>3.4 kg to 6.6 kg</td>
<td>51 mg to 99 mg</td>
<td>1 x 100 mg vial</td>
</tr>
<tr>
<td>6.7 kg to 10 kg</td>
<td>100.5 mg to 150 mg</td>
<td>1 x 100 mg vial + 1 x 50 mg vial</td>
</tr>
<tr>
<td>10.1 kg to 13.3 kg</td>
<td>151.5 mg to 199.5 mg</td>
<td>2 x 100 mg vials</td>
</tr>
<tr>
<td>13.4 kg to 16.6 kg</td>
<td>201 mg to 249.5 mg</td>
<td>2 x 100 mg vials + 1 x 50 mg vial</td>
</tr>
<tr>
<td>16.7 kg to 20 kg</td>
<td>250.5 mg to 300 mg</td>
<td>3 x 100 mg vials</td>
</tr>
</tbody>
</table>

**Reminder:** The provider must retain copies of all documentation for six (6) years (10 C.C.R. 2505-10, Section 8.040.2).
For infants in the first year of life: (Check at least one of the following AND indicate diagnosis code)

- Any infant up to 12 months of age, born before 29 weeks 0 days gestation.
- For infants born before 32 weeks 0 days gestation AND Chronic Lung Disease (CLD) of prematurity with greater than 21% oxygen use for at least 28 days after birth
- An infant with cystic fibrosis with clinical evidence of CLD AND/OR nutritional compromise
- An infant with neuromuscular disease or pulmonary abnormality AND is unable to clear secretions from the upper airways
- An infant who undergoes cardiac transplantation during the RSV season.
- Infants with hemodynamically significant heart disease (acyanotic heart disease) defined as having one or more of the following:
  - Infants receiving medication to control congestive heart failure and will require cardiac surgical procedures;
  - Infants with moderate to severe pulmonary hypertension
- An infant with cyanotic heart defects AND in consultation with a pediatric cardiologist AND both of the following:
  - Requirement of >21% oxygen for at least 28 days after birth
  - Continues to require medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy)
- An infant who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplantation, receiving chemotherapy)

ICD 10-CM Code: ____________________________
SYNAGIS® PHARMACY BENEFIT® PRIOR AUTHORIZATION REQUEST FORM

For children in the second year of life: (Check at least one of the following AND indicate diagnosis code)

☐ For children born before 32 weeks 0 days gestation AND Chronic Lung Disease (CLD) of prematurity AND Requirement of >21% oxygen for at least 28 days after birth AND continue to require medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy)

☐ A child who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplantation, receiving chemotherapy)

☐ Children with manifestation of severe lung disease: (Choose one of the following AND add Diagnosis code)

☐ Previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities of chest radiography or chest computed tomography that persist when stable OR

☐ Weight for length less than the 10th percentile.

☐ A child who undergoes cardiac transplantation during the RSV season.

ICD 10-CM Code:

ICD 10-CM Code:

ICD 10-CM Code:

Has the member received prior doses?  ☐ Yes  ☐ No

If yes, what date was the last dose received? ________________________________

Provider attests that Synagis® will be administered in the patient’s home or long-term care facility.  ☐ Yes  ☐ No

If no, doses administered in a physician’s office or clinic must be billed through the medical benefit unless a patient cannot access home health services.

Provider attests home health services are not available to the patient.  ☐ Yes  ☐ No

If no, please visit https://hcpf.colorado.gov/par for information on how to submit a medical PAR for Synagis®.

Prescriber Signature (Required) ________________________________ Date __________________

By signature, the Prescriber confirms the criteria information above is accurate and verifiable in patient records.

Fax This Form to:

HEALTH FIRST COLORADO PRIOR AUTHORIZATIONS
FAX NUMBER: 1-800-424-5881 (FORMS NEED TO BE FAXED FOR APPROVAL)
PA HELP DESK: 1-800-424-5725

2016, Magellan Health, Inc. All Rights Reserved.
Revision Date: 11/21/2022